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Therapeutic strategies formultiplemyeloma (MM) have changed dramatically over the past decade. Thus, the role
of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this
evidence-based review,wehavecriticallyanalyzed thedata fromthemost recentclinical trials tobetterunderstand
how to incorporate HCTandwhenHCT is indicated.We have provided our recommendations based on strength of
evidence with the knowledge that ongoing clinical trials make this a dynamic ﬁeld. Within this document, we
discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of
tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.
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ty for Blood and Marrow Transplantation.The landscape of multiple myeloma (MM) has changed
dramatically over the last several years, with numerous new
therapies and improved patient outcomes [1]. Since the last
publication of American Society for Blood and Marrow
Transplantation (ASBMT) guidelines for MM (2003) the
Table 1
Levels of Evidence [4]
1þþ High-quality meta-analyses, systematic reviews of RCTs,
or RCTs with a very low risk of bias.
1þ Well-conducted meta-analyses, systematic reviews of RCTs,
or RCTs with a low risk of bias.
1 Meta-analyses, systematic reviews of RCTs, or RCTs with
a high risk of bias.
2þþ High-quality systematic reviews of case-control or cohort
studies; high-quality case-control or cohort studies with
a very low risk of confounding, bias, or chance and a high
probability that the relationship is causal.
2þ Well-conducted case-control or cohort studies with a
low risk of confounding, bias, or chance and a moderate
probability that the
relationship is causal.
2 Case-control or cohort studies with a high risk of
confounding, bias, or chance and a signiﬁcant risk
that the relationship is not causal.
3 Nonanalytic studies, eg, case reports or case series.
4 Expert opinion.
RCT indicates randomized controlled trial. Reproduced from: A new system
for grading recommendations in evidence based guidelines, Harbour R,
Miller J. BMJ 2001;323:334-336. With permission from BMJ Publishing
Group Ltd.
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has evolved signiﬁcantly. As the utilization of autologous
hematopoietic stem cell transplantation (auto-HCT) for MM
has increased, the demographics of this therapy have shifted
to provide improved outcomes for patients over 40 and 60
years old [2]. These exciting changes require a critical review
of the role of hematopoietic stem cell transplantation (HCT)
for this disease.
Data published between June 1, 2002 and December 31,
2014 were reviewed. We searched the PubMed database
using the terms multiple myeloma and transplant as well as
topics relevant to each particular discussion section. Only
ﬁnalized peer-reviewed publications were included for re-
view. Studies were graded according to the criteria set forth
by the Steering Committee for Evidence-Based Reviews from
ASBMT [3], adapted from the original recommendations of
the Scottish Intercollegiate Guidelines Network Grading Re-
view Group [4]. Levels of evidencewere assessed and a grade
was assigned to each recommendation following the criteria
in Tables 1 and 2.
AUTO-HCT VERSUS CONVENTIONAL CHEMOTHERAPY
A signiﬁcant survival advantage of high-dose chemo-
therapy (HDC) and auto-HCTover conventional chemotherapyTable 2
Grades of Recommendation [4]
A At least 1 meta-analysis, systematic review, or RCT rated as 1þþ
and directly applicable to the target population or a systematic
review of RCTs or a body of evidence consisting principally
of studies rated as 1þ, directly applicable to the target
population, and demonstrating overall consistency of results.
B A body of evidence including studies rated as 2þþ, directly
applicable to the target population, and demonstrating overall
consistency of results or extrapolated evidence from studies
rated as 1þþ or 1þ.
C A body of evidence including studies rated as 2þ, directly
applicable to the target population, and demonstrating overall
consistency of results or extrapolated evidence from studies
rated as 2þþ.
D Evidence level 3 or 4 or extrapolated evidence from studies
rated as 2þ.
Reproduced from: A new system for grading recommendations in evidence
based guidelines, Harbour R, Miller J. BMJ 2001;323:334-336. With
permission from BMJ Publishing Group Ltd.was reported in the pivotal Intergroupe Francophone du
Myelome (IFM) trial in 1996 [5]. Thereafter, several additional
trials have been published to support these ﬁndings, the de-
tails of which are outlined in Table 3. Of the 6 trials presented,
4 have shown a beneﬁt in progression-free survival (PFS) and
3 have shown a beneﬁt in overall survival (OS) for auto-HCT.
Of note, only 1 of these studies was published after 2010. A
meta-analysis from 2007 also found an improvement for PFS
in the auto-HCT arm but no beneﬁt in OS [12]. Although the
most recently published prospective trial by Palumbo et al.
employed 2 cycles of melphalan 200mg/m2, patients received
a more relevant lenalidomide-based induction [11]. In addi-
tion, an analysis of toxicity done by Fermand et al. [8] also
favored the auto-HCT arm.
Based on these data, in conjunction with the previously
reported results from the IFM study, we recommend HDC
and auto-HCT as consolidative therapy for patients with MM
(grade A recommendation). Prospective studies are in
progress to further clarify if this recommendation will be
upheld in the era of novel agents for induction therapy.TIMING OF AUTO-HCT: EARLY VERSUS LATE
A systematic literature search did not identify any pro-
spective, randomized trials comparing early versus delayed
auto-HCT in MM since the publication of 2003 guidelines.
Although the randomized study by Fermand et al. [8] showed
a signiﬁcant event-free survival (EFS) beneﬁt and longer time
without symptoms, treatment, or treatment toxicity with
early transplantation in MM patients receiving conventional
inductions, no such prospective data are available for
MM patients receiving modern (immunomodulatory drug
(IMiD)- or proteasome inhibitor-based) induction regimens.
Two retrospective studies have examined this issue more
recently. Kumar et al. and Dunavin et al. retrospectively
evaluated the role of early (within 12 months of diagnosis)
versus delayed auto-HCT in MM patients (n ¼ 290) who
received IMiD-based inductions [13] or any novel induction
[14]. The time to progression and OS from time of diagnosis
were similar between the 2 groups in both studies.
These retrospective studies suggest feasibility of delayed
auto-HCT in the modern era, but they are not a substitute for
randomized data. The reason for employing early versus
delayed transplantation in individual patients in these studies
is not clear. Hence, which subset of MM patients is likely to
beneﬁt the most from delayed auto-HCT remains unknown.
More importantly, no patient-reported outcome or quality of
life data comparing early versus late auto-HCT in the modern
era are available. Similarly, reliable cost effectiveness data
comparing early transplantation against continuation of often
expensive novel agent inductions are not available. Finally, in
carefully selected MM patients receiving lenalidomide-based
inductions with intent for a delayed auto-HCT, the impor-
tance of early stem cell collection and cryopreservation cannot
be overemphasized [15-17]. Further recommendations on
stem cell mobilization are discussed in the recently published
ASBMT guidelines [18,19].
Therefore, based on available prospective data, we
continue to recommend early (up-front) auto-HCT. However,
given the recent and rapid changes in induction therapy, it is
also reasonable to consider enrollment on a clinical trial that
addresses the question of transplantation timing. The multi-
center DFCI 10-106 (NCT01208662) trial is ongoing to address
this exact question in the era of novel combination therapy.
Table 3
Summary of Prospective Randomized Trials Comparing Conventional Chemotherapy with Auto-HCT
Author Study Details Response Data PFS Data OS Data Level of
Evidence
Comments
Child,
2003 [6]
Pts < 65 yr
ABCM/IFN maintenance
vs Dox-Methylpred-Cy/
auto-HCT
CR 8% versus 44%
favoring auto-HCT
group (P ¼ .04)
Favoring auto-HCT
group (P < .001)
Favoring auto-HCT
group (P < .04)
1þþ
Blade,
2006 [7]
Pts < 65 yr
VBMCP/VBAD/ 8 additional
cycles versus auto-HCT
(high dose Mel  TBI)
CR 11% versus 30%
favoring auto-HCT
group (P ¼ .002)
No difference No difference 1þþ
Fermand,
2005 [8]
Pts < 65 yr
VMCP versus CHOP/VAMP/
auto-HCT with Mel
versus Bu/Mel
P value not reported EFS favoring auto-HCT
group (P ¼ .07)
No difference 1þþ Time without symptoms,
treatment, and treatment
toxicity (TwiSTT) longer
in auto-HCT arm (P ¼ .03).
Palumbo,
2004 [9]
Pts 50-70 yr
MP  6 versus Mel
100 mg/m2  2
nCR ¼ 6% versus
25% (P ¼ .002)
EFS at 3 yr favoring
auto-HCT group 16%
versus 37% (P < .001)
OS at 3 yr favoring
auto-HCT group 62%
versus 77% (P < .001)
1þþ
Barlogie,
2006 [10]
VAD/ VBMCP versus
auto-HCT with Mel/TBI/
 IFN maintenance
No difference No difference No difference 1þþ
Palumbo,
2014 [11]
Len-Dex þCy- mob/
MPR  6 versus Mel
200 mg/m2 auto-HCT  2;
all randomized to 
Len maintenance
P value not
reported
Favoring auto-HCT
group (P < .001)
Favoring auto-HCT
group (P < .02)
1þþ Maintenance improved
PFS but not OS
Pts indicates patients; ABCM, doxorubicin, carmustine, cyclophosphamide, melphalan; Dox, doxorubicin; methylpred, methylprednisolone; Cy, cyclophos-
phamide; VBMCP, vincristine, BCNU, melphalan, cyclophosphamide, prednisone; VBAD, vincristine, BCNU, doxorubicin, dexamethasone; Mel, melphalan; TBI,
total body irradiation; VMCP, vincristine, melphalan, cyclophosphamide, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; VAMP,
vincristine, doxorubicin, methylprednisolone; Bu, busulfan; TwiSTT, timewithout symptoms, treatment, or treatment toxicity; MP, melphalan, prednisone; nCR,
near complete response; VAD, vincristine, doxorubicin, dexamethasone; Len, lenalidomide; Dex, dexamethasone; MPR, melphalan, prednisone, lenalidomide.
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The evidence to support a ﬁrst auto-HCT for refractory
disease (deﬁned as < partial response to induction therapy)
is generally limited to older retrospective studies (Table 4).
Based on this literature, even patients with refractory disease
can gain some beneﬁt from auto-HCT, though this is probably
less true for patients with overtly progressive disease [23]. It
is also important to mention that data from these studies are
from the early 2000s, such that a patient refractory to novel
therapies may have a different clinical course. Retrospective
analysis also suggests that, although additional lines of
therapy before auto-HCT may improve response depth in
patients with less than a partial remission, this does not
seem to impact long-term survival [24]. Though prospective
evidence is lacking, we recommend consideration of a ﬁrst
auto-HCT for patients with refractory disease (grade C).
FACTORS TO CONSIDER FOR AUTO-HCT: AGE AND
COMORBIDITIES
Several groups have retrospectively examinedwhether age
should be considered as a factor in patient selection forTable 4
Summary of Studies Examining Role of Auto-HCT for Patients with Refractory MM
Author Study Details Response Data
Singhal,
2002 [20]
n ¼ 43 refractory pts;
C-VAMP/auto-HCT
40% CR
Kumar,
2004 [21]
n ¼ 50 refractory pts versus
n ¼ 101 chemosensitive pts,
all receiving auto-HCT
20% versus 35% CR (P ¼
Alexanian,
2004 [22]
89 refractory pts; VAD/ auto-HCT
versus 45 refractory pts without
auto-HCT
16% CR in auto-HCT grou
Rosinol,
2012 [23]
n ¼ 80 primary refractory: 49 with
SD and 31 with PD. VBMCP/VBAD
Mel-based auto-HCT and second auto
No difference in respons
after ﬁrst auto-HCT
C-VAMP indicates vincristine, doxorubicin, methyleprednisolone; SD, stable diseasauto-HCT [25-27]. In all of these studies, age> 65 years has not
been found to be a limiting factor for transplantation success.
The hematopoietic cell transplantationespeciﬁc comorbidity
index (HCT-CI) has been shown to predict risk of nonrelapse
mortality and survival after allo-HCT. Saad et al. analyzed
outcomes of 1156patients in the Center for International Blood
andMarrow Transplant Research (CIBMTR) registry after auto-
HCT and high-dose melphalan [28]. On multivariate analysis,
OS was inferior in groups with HCT-CI score of 1 to 2 (relative
risk, 1.37, [95% conﬁdence interval, 1.01 to 1.87]; P ¼ .04) and
HCT-CI score>2 (relative risk,1.5 [95%conﬁdence interval,1.09
to 2.08]; P ¼ .01). OS was also inferior with Karnofsky perfor-
mance status< 90 (P < .001). However, it is important to note
that the treatment-related mortality at 1 year was equivalent
(2%) for patients with a HCT-CI score of 0 or >2.
We recommend that age not be used as a selection factor
(grade C). However, an HCT-CI score of >2 or Karnofsky per-
formance status <90 can warrant additional consideration
before proceeding with auto-HCT. Though the evidence is
mainly retrospective, it is unlikely that prospective random-
ized data will be forthcoming to truly answer this question.PFS Data OS Data Level of
Evidence
Similar between refractory
and responsive pts
2þ
.063) 1-yr PFS similar
between groups
2þ
p 27 mo longer in auto-
HCT group (P < .01)
2þ
e PFS shorter in
PD pts (.6 versus
2.3 yr, P ¼ .0004)
OS shorter in PD pts
(1.1 versus 6 yr, P ¼ .00002)
2þ
e; PD, progressive disease.
Table 5
Summary of Studies Examining Impact of Cytogenetics on Outcomes after Auto-HCT
Author Cytogenetics/FISH Studied Effect on PFS Effect on OS Level of
Evidence
Falcon, 2001 [29] Abnormality of 13 by FISH Adverse prognostic factor (P < .001) 2þ
Chang, 2004 [30] t(4:14) Signiﬁcantly worse (P ¼ .0003) Signiﬁcantly worse (P ¼ .0001) 2þ
Moreau, 2002 [31] t(4:14) EFS Signiﬁcantly worse (P < .000) Signiﬁcantly worse (P ¼ .002) 2þ
Chang, 2005 [32] p53 deletion Signiﬁcantly worse (P ¼ .0324) Signiﬁcantly worse (P ¼ .0008) 2þ
Chang, 2010 [33] Del 1p21 Signiﬁcantly worse (P < .001) Signiﬁcantly worse (P ¼ .001) 2þ
Avet-Loiseau,
2007 [34]
Composite FISH for del(13),
t(11;14), t(4;14), hyperdiploidy,
MYC translocations, and del(17p)
Adverse results for t(4;14),
del(17p) (EFS)
Adverse results for t(4;14),
del(17p) (EFS)
2þþ
Fonseca, 2003 [35] Composite of t(4;14), t(14; 16)
and del17p
Signiﬁcantly worse (P < .001) 2þ
Neben, 2010 [36] Composite of t(4;14) and del17p
with ISS II or III
Signiﬁcantly worse (P < .001) 2þ
ISS indicates International Staging System.
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Several investigators have reported retrospective ana-
lyses of cytogenetic data for MM patients undergoing auto-
HCT (Table 5). Although these studies of auto-HCT patients
conﬁrm the inferior outcome expected with high-risk cyto-
genetics, there are no prospective studies to determine if
patients with any particular cytogenetic abnormality should
not undergo auto-HCT or, conversely, whether any particular
cytogenetic abnormality gains speciﬁc beneﬁt from auto-
HCT over conventional chemotherapy. However, the poor
outcomes associated with some of these abnormalities make
a case for alternative options for these patients. Therefore,
we recommend serious consideration of a clinical trial for
patients with high-risk cytogenetics, particularly del17p or
t(4:14) (grade C).WHAT IS THE OPTIMAL PREPARATIVE REGIMEN FOR
HDC AND AUTO-HCT?
The IFM trial establishedmelphalan 200mg/m2 (Mel 200)
as the standard to which all other MM preparative regimens
for auto-HCT are compared [37]. Table 6 summarizes the
clinical trials with the highest degree of evidence in
comparing alternative regimens to Mel 200. These studies
focus on agents traditionally used for conditioning or add
chemotherapy agents more often used in the treatment of
hematologic malignancies other than myeloma. More
recently, several single-arm studies have incorporated novel
agents used routinely in the induction treatment of MM
[42,43]. Although this may be a promising approach, no
prospective controlled studies are available for higher level
evidence.
Based on the studies performed, no combination of
agents to date has proven safer or more effective than MelTable 6
Summary of Prospective Studies Examining Preparative Regimens for Auto-HCT in
Author Regimens Studied PFS/OS
Lahuerta, 2010 [38] BuMel versus Mel 200 Median PFS 41 m
median OS 77 ve
Fenk, 2005 [39] Idarubicin/Mel/Cy versus
Mel 100 mg/m2  2; IFN
maintenance for all patients
No difference in
TRM 20% versus
Vela-Ojeda, 2007 [40] BCNU/etoposide/Mel versus Mel 200 Median OS 36 m
Palumbo, 2010 [41] Mel 200 mg/m2  2 versus
Mel 100 mg/m2  2
Median PFS 31.4
5-yr OS 61.8 ver
VOD indicates veno-occlusive disease; TRM, treatment-related mortality.200 mg/m2 as a preparative regimen. Thus, we recommend
Mel 200 as the standard regimen for MM conditioning,
outside of clinical trials (grade A). However, ongoing research
that incorporates novel agents such as bortezomib may ul-
timately lead to increases in PFS and OSwithout contributing
to excessive toxicity. Though beyond the scope of this review,
recommendations on chemotherapy dosing in obese patients
or patients with renal insufﬁciency are discussed in a recent
review and ASBMT guidelines on these topics [44,45].THE ROLE OF TANDEM AUTO-HCT FOR MULTIPLE
MYELOMA
The advantage of an auto-HCT strategy that routinely in-
corporates tandem transplantations remains an open ques-
tion. Table 7 details the prospective, randomized controlled
trials of single versus tandem auto-HCT for MM. The land-
mark IFM trial demonstrated a beneﬁt from the tandem
auto-HCT in all parameters: EFS, relapse-free survival (RFS),
and OS [46]. A subset analysis indicated that the group
achieving less than a very good partial response beneﬁted
most from the tandem procedure. However, the Bologna 96
and the HOVON 24 trials showed the tandem arm to beneﬁt
EFS but not OS [47,48]. Finally, in the HOVON-65/GMMG-
HD4 trial, a separate analysis comparing the single versus
tandem approach showed an improvement in PFS but not in
OS [49]. However, assignment to the treatment arm was
based on geographic location and the trial had not been
designed to prospectively ask this question.
In addition to the trials listed in Table 7, there have been
several single-arm trials that have examined this question
with comparisons made to historical controls [50-53]. The
vast majority of these have not suggested superiority of the
tandem approach, though the conditioning regimens varyMM
Level of
Evidence
Comments
o versus 31 mo;
rsus 70 mo (P ¼ .40)
1 Excessive VOD caused closing
of Bu/Mel arm
EFS and OS
0% in Mel 200 arm
1þ Standard therapy better,
less toxicity
o versus 86 mo (P ¼ .08) 1 No beneﬁt for oral Mel regimen
versus 26.2 mo (P ¼ .01);
sus 47.7% (P ¼ .13)
1þþ Mel 200 mg/m2 should be
considered standard, though was
in tandem approach in this study
Table 7
Prospective Studies Examining Single versus Tandem Auto-HCT
Author Conditioning Regimen TRM/ORR EFS OS Level of
Evidence
Attal, 2003 [46] TBI 8 Gy and Mel 140 mg/m2 versus
Mel 140 mg/m2 followed by TBI 8 Gy
and Mel 140 mg/m2;
IFN maintenance offered to all pts
TRM 4% versus 6%
ORR 84% versus 88%
Favoring tandem arm;
25 mo versus 36 mo (P ¼ .03)
Favoring tandem
arm 48 versus 58
mo (P ¼ .01)
1þþ
Cavo, 2007 [47] Mel 200 mg/m2 d-2 versus
Mel 200 mg/m2 followed by
Mel 140 mg/m2 d-2 and
Bu 1 mg/kg PO  12 d-5-to -3;
maintenance IFN offered to all pts
TRM 3% versus 4%
ORR NS
CR þ nCR 33% versus
47% (P ¼ .01)
Favoring tandem arm;
23 versus 35 mo (P ¼ .001)
65 mo versus
71 mo (P ¼ .9)
1þþ
Sonnevold, 2007 [48] Mel 70 mg/m2 i.v.  2 versus
Mel 70 mg/m2 i.v.  2;
Cy 120 mg/kg i.v. and TBI 9 Gy;
maintenance IFN offered to all pts
TRM not stated; ORR
88% for entire group
CR 13% versus 32%
Favoring tandem arm;
21 mo versus 22 mo (P ¼ .013)
55 mo versus
50 mo (P ¼ .51)
1þþ
ORR indicates overall response rate; NS, not signiﬁcant; PO, orally.
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have included novel agents, such as thalidomide or borte-
zomib, in a tandem transplantation algorithm [54-57].
Although the results of these trials are encouraging, the lack
of a single HCT control arm makes their results difﬁcult to
interpret, particularly as induction regimens evolve rapidly.
Finally, Barlogie et al. have published their updated results
with the total therapy approach [58-61]. With incorporation
of novel therapeutics to rigorous induction followed by tan-
dem HCT, consolidation, and maintenance, the single-center
results have continued to improve. However, the treatment
algorithms are complex and the contribution of each
component, speciﬁcally the importance of using a tandem
HCT platform, to the overall response is difﬁcult to ascertain.
Twometa-analyses addressing the role of tandemHCT for
MM have been published [62,63], both of which suggest that
there is no apparent improvement in either EFS or OS using a
tandem approach. Based on the conﬂicting data from the
prospective randomized trials and the above meta-analyses,
there is insufﬁcient evidence to support tandem auto-HCT as
the standard of care for myeloma patients. However, there
are cases when this may be considered, based in the IFM
data, in patients with less than a very good partial response
after a ﬁrst auto-HCT (grade D) or as part of a clinical trial. It is
important to note that in the current era of IMiDs and pro-
teasome inhibitors, the role of up-front tandem trans-
plantation has not yet been decided. Results from an
upcoming integrated analysis of 4 phase III European trials
[64] and the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN) 0702 trial (NCT01109004), in which one
third of patients have been randomized to a tandem
melphalan 200 mg/m2 arm, may ultimately alter future
transplantation algorithms.
AFTER AUTO-HCT: RECOMMENDATIONS FOR FOLLOW-
UP
Although not based on prospective, randomized studies,
there have been guidelines established for timing and tests
for follow-up [65,66]. Our recommendations are thus based
mainly on consensus opinion in the setting of retrospective
data. At present, the International Myeloma Working Group
(IMWG) uniform response criteria [67] are the preferred
criteria to determine the best response to treatment.
For measureable serum or urine myeloma proteins, the
ﬁrst measurement is taken 2 to 3 months after auto-HCT, and
then followed every 3 to 4 months thereafter [65]. Although
bone marrow (BM) aspiration/biopsy is required todocument any complete response (CR), there is no evidence
to indicate that it is required for follow-up if there are
measurable serum or urine markers [66]. It should be noted
that retrospective data suggests that patients with less BM
disease burden have improved outcomes, evenwith negative
serum and urine markers [68].
The role of various imaging modalities after trans-
plantation is controversial. Current retrospective data suggest
that serial skeletal survey is not useful for earlier detection of
disease relapse or progression [69] and this is the opinion
upheld by the IMWG. Although serial magnetic resonance
imaging may assist in following response to therapy [70], its
role in routine surveillance is not deﬁned. In patients with
known lesions at diagnosis, positron emission tomography-
computed tomography (PET/CT) after transplantation can be
useful to predict long-term outcome [71]. However, PET/CT
imaging as a routine surveillance for asymptomatic patients
after transplantation is not yet recommended.
Recently, the IMWG panel approved deﬁnitions of immu-
nophenotypic CR andmolecular CR to be incorporated into the
IMWG criteria [72]. In addition, several studies have prospec-
tively employed multiparameter ﬂow cytometry and shown
improved outcome in minimal residual disease (MRD)enega-
tive patients after auto-HCT [73,74]. The European Myeloma
Network has developed a consensus on for plasma cell
enumeration, sample preparation, gating, and immunophe-
notype for clonality assessment [75]. However, there is still
considerable variability in the United States regarding ﬂow
cytometric deﬁnitions of abnormal plasma cells [76].
Recommendations for Follow-up after Auto-HCT:
A Position Statement Reviewed and Agreed upon by a
Consensus Panel from the ASBMT
1. In patients with measurable disease, monitoring
should start 2 to 3months after auto-HCTand continue
every 3 months thereafter with serum and/or urine M-
protein, serial involved free light chain (FLC) assay, and
serum FLC ratio. BM biopsymay be required in patients
with oligosecretory plasma cell disorder and in pa-
tients with no measurable disease.
2. If documentation of response is desired, BM exami-
nation and FLC ratio are required to document CR, near
CR, and stringent CR status or to assess cause of
persistent cytopenias.
3. IMWG uniform response criteria should be used to
determine disease status after auto-HCT.
Table 8
Summary of Prospective, Randomized Studies using Consolidation after Auto-HCT
Author Study Details Response Data PFS Data OS Data Level of
Evidence
Comments
Mellqvist, 2013 [77] Bortezomib  20
doses versus no
consolidation
Upgrade from PR
favoring consolidation
arm (P ¼ .007)
Favoring consolidation
arm (P ¼ .05)
No difference 1þþ More fatigue in
consolidation arm;
beneﬁts mainly for
pts in < VGPR
Spencer, 2009 [78] Thal-pred versus
prednisone
CR þ VGPR rate favoring
Thal-pred arm (P < .001)
Favoring Thal-pred arm
(P < .001)
Favoring Thal-pred
arm (P ¼ .004)
1þþ
Cavo, 2012 [79] VTD versus TD
consolidation; dex
maintenance for all
CR/nCR rate favoring
VTD arm (P ¼ .02)
Favoring VTD arm
(P ¼ .042)
No difference 1þþ Tandem auto-HCT
setting
PR indicates partial response; VGPR, very good partial response; Thal, thalidomide; VTD, bortezomib, thalidomide, dexamethasone; TD, thalidomide,
dexamethasone.
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relapse or progression of disease after HCT, serial
radiography/magnetic resonance imaging or PET scan
is not routinely required. However, these tests may be
used to follow response to therapy or evaluate new
symptoms.
5. MRD testing after auto-HCT in MM can reveal patients
at risk for poorer outcomes and should be considered
for disease evaluation (grade B). If MRD testing is
attempted, multiparametric ﬂow cytometry following
the European Myeloma Network consensus guidelines
should be the method of choice.
AFTER AUTO-HCT: RECOMMENDATIONS FOR
TREATMENT
In the era of novel agents, consolidation and maintenance
strategies are attractive options after auto-HCT. Table 8
summarizes prospective, randomized trials examining
post-transplantation consolidation, deﬁned as a planned
course of full or intermediate dose cycles. Of note, only the
study by Mellqvist et al. [77] compared consolidation bor-
tezomib with no treatment, whereas the other 2 studies
compared consolidation strategies [78,79]. In the ﬁrst trial,
consolidation bortezomib improved PFS but not OS. Main-
tenance strategies with glucocorticoids [80,81] or interferon
[10,82,83] have largely been abandoned because of excessive
toxicity and/or absence of beneﬁt. Table 9 summarizesTable 9
Summary of Prospective Studies Using Novel Agents for Maintenance Therapy afte
Author Study Details Response Data PFS Data
Attal,
2006 [84]
No maintenance
versus pamidronate
versus Thal-pamidronate
CR favoring
Thal-pamidronate
(P ¼ .03)
EFS favoring
Thal-pamidr
(P < .009)
Maiolino,
2012 [85]
Dex versus Thal-dex No difference Favoring Th
(P ¼ .002)
Stewart,
2013 [86]
No maintenance versus
Thal-pred
Not reported Favoring Th
(P < .0001)
Morgan,
2012 [87]
No maintenance
versus Thal
Favoring Th
(P < .001)
McCarthy,
2012 [88]
Len versus placebo Not reported Favoring Len
(P < .001)
Attal,
2012 [89]
Consolidation
Len/Len maintenance
versus placebo
CR/VGPR rates
favoring Len
maintenance
(P ¼ .009)
Favoring Len
maintenanc
(P < .001)
Palumbo,
2014 [11]
MPR  6 and Mel 200
auto-HCT  2 arms both
randomized to  Len
maintenance
Not reported for
non-maintenance
arms
For auto-HC
PFS favored
maintenanc
64.7 versus
HRQoL indicates health-related quality of life.prospective randomized trials using novel agents for main-
tenance therapy after auto-HCT. We included only trials that
studied the effect of additional therapy after auto-HCT with
no randomization before auto-HCT.
Maintenance thalidomide was associated with improved
OS in at least 1 trial [84]; however, the increased toxicities and
inferior outcomes in health-related quality of life [86] have
made this strategy less appealing. Three randomized
controlled trials have examined maintenance lenalidomide
[11,88,89].Althoughall showed improvedPFS, only theCALGB
trial demonstrated an improvement in OS. It should be noted
that 2 of these trials [88,89] demonstrated an increase in
second primary malignancies (SPM) in the maintenance
lenalidomide arms. In a recently publishedmeta-analysis of 8
randomized controlled trials, a beneﬁt in both PFS andOSwas
seen for IMiD-basedmaintenance [90]. Thiswas largely based
ondatawith thalidomide but suggested that longer follow-up
with lenalidomidewasneeded. Though therehas beendata to
suggest that bortezomib maintenance may also be used [49],
it has not been as rigorously studied as maintenance alone
against an appropriate control.
Recommendations for Therapy after Auto-HCT
1. Consolidation after auto-HCT is not routinely recom-
mended but can be considered in the setting of a
clinical trial.r Auto-HCT
OS Data Level of
Evidence
Comments
onate
Favoring
Thal-pamidronate
(P < .04)
1þþ Increased neuropathy,
fatigue, constipation,
neutropenia in
Thal-pamidronate arm
al-dex No difference 1þþ
al-pred No difference 1þþ Worse HRQoL in
Thal-pred arm
al No difference 1þþ Meta-analysis suggested
beneﬁt of Thal on OS
Favoring Len
(P ¼ .03)
1þþ More toxicities and
SPMs in Len arm
e
No difference 1þþ More toxicities and
SPMs in Len arm
T group
e arm:
37.4 mo
No difference due
to maintenance for
auto-HCT group
1þ Maintenance improved
PFS but not OS; SPMs
not increased in
maintenance arm
Table 10
Recent Retrospective Studies Evaluating Second Salvage Auto-HCT for
Relapsed MM
Authors Years of
Study
N NRM, % Median
PFS, mo
Median
OS, mo
Auner, 2013 [96] 1994-2001 83 d 15.5 31.5
Chow, 2013 [97] 1992-2011 30 7 22 45
Gonsalves, 2013 [98] 1994-2009 98 4 25.3 33
Lemieux, 2013 [99] 1995-2009 81 d 18 48
Michaelis, 2013 [100] 1995-2008 187 4 11.2 30
Jimenez-Zepeda,
2012 [101]
1992-2009 81 2.6 16.4 53
Shah, 2012 [102] 1992-2008 44 2 12.3 31.7
Blimark, 2011 [103] 1996-2007 66 NR 8.5 24
Cook, 2011 [104] 1990-2002 106 7 d 46.8
Fenk, 2011 [105] 1993-2008 55 5.9 14 52
Burzynksi, 2009 [106] 1999-2007 25 8 12 19
Olin, 2006 [107] 1998-2007 41 7 8.5 20.7
Elice, 2006 [108] 1993-2003 26 d 14.8 38.1
Qazilbash, 2006 [109] 1992-2004 14 7 6.8 29.5
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(thalidomide or lenalidomide) is recommended unless
a contraindication exists (grade A). In most cases,
lenalidomide is preferred because of improved survival
data in the era of novel agents.
3. In patients with high-risk disease with renal failure or
adverse chromosome changes, posteauto-HCT borte-
zomib consolidation and maintenance may be
considered (grade D).
LONG-TERM MANAGEMENT OF MM PATIENTS AFTER
AUTO-HCT
After auto-HCT, patients are often referred back to their
community oncologist. It is imperative that the trans-
plantation physician collaborate with referring hematolo-
gists to determine a follow-up plan.With improving survival,
patients now face concerns for SPM, thrombosis, anti-
coagulation, bone complications, and economic and rela-
tionship issues.
Though there are very little prospective data on the post-
transplantation population, our experience suggests that the
principles from the induction period can apply. Thus, based
on expert panel consensus, we recommend resumption of
bisphosphonate therapy [91] as per IMWG recommenda-
tions [92] and prophylactic anticoagulation or antiplatelet
therapy for patients receiving thalidomide or lenalidomide
therapy [93,94]. Because of the increased risk of SPMs in the
setting of lenalidomide maintenance therapy [88,89], pa-
tients should be followed closely and monitored for hema-
tological and nonhematological cancers.
SECOND TRANSPLANTATION AS SALVAGE THERAPY FOR
RELAPSED MM
Unfortunately, the majority of patients treated with an
initial auto-HCT eventually relapse. Although there are a
number of new drugs for treating relapsed disease, a second
transplantation remains a viable treatment option for pa-
tients and should be considered in the arsenal of available
therapeutic options for these patients. Current National
Comprehensive Cancer Network guidelines recommend that
all patients who are eligible for auto-HCT be considered for
peripheral blood apheresis sufﬁcient for 2 autografts in the
event a second autograft is necessary in the salvage setting
[95].
Until recently, most of the data regarding the efﬁcacy of a
second auto-HCT have been limited to single-institution,
retrospective studies that include a relatively small number
of patients (Table 10). However, the ﬁrst prospective phase III
study of second salvage auto-HCT was recently reported
[110]. Salvage auto-HCT was compared with salvage cyclo-
phosphamide in patients who had relapsed disease after
previous auto-HCT. Patients in the salvage auto-HCT had a
superior PFS (P < .0001) but not OS.
The retrospective studies have consistently shown that
salvage second auto-HCT is a viable and safe option for pa-
tients with relapsed disease. The most consistent ﬁnding
among these studies is that longer progression-free interval
from ﬁrst auto-HCT is associated with better outcomes for
PFS and OS. In contrast to this, patients with rapid relapse
(<12months) do not derive signiﬁcant beneﬁt from a second
auto-HCT. When examined as a group, the overall response
rate was 64.3% (95% conﬁdence interval, 27.3% to 97.4%) with
a median PFS of 12.3 months and median OS of 12.3 months,
which are comparable to outcomes with other salvage regi-
mens [111]. Of note, there are no prospective data regardingthe use of maintenance therapy after second salvage auto-
HCT. Finally, when comparing second auto-HCT to alloge-
neic HCT (allo-HCT), patients who undergo allo-HCT may
suffer higher nonrelapse mortality with inferior OS [109].
Recommendations on the Role of Salvage Second Auto-
HCT
Second auto-HCT is a safe and efﬁcacious treatment mo-
dality for relapsed MM and should be considered (grade B).
We note that this grade is based on data with superior PFS as
an outcome, but think that this is an appropriate endpoint in
the relapsed setting.
Patients with longer progression-free interval after
ﬁrst auto-HCT have better outcomes after salvage second
auto-HCT. It is recommended that the minimum length of
remission be at least 12 months for consideration of second
auto-HCT as salvage therapy (grade D).
The role of maintenance therapy after salvage second
auto-HCT is unclear.
ALLOGENEIC TRANSPLANTATION FOR MYELOMA
The role allo-HCT in MM remains controversial and
poorly deﬁned. Interest in allo-HCT for MM has been sus-
tained by the promise of a myeloma-free donor cell graft and
the possibility of an immune-mediated graft-versus-
myeloma effect [112-114]. Traditional myeloablative condi-
tioning and its associated toxicities have given way to more
tolerable reduced-intensity conditioning (RIC) regimens.
Often performed after optimal cytoreduction with a con-
ventional auto-HCT, this approach uncouples myeloablation
(achieved by the auto-HCT) from the graft-versus-myeloma
effect mediated by establishing donor chimerism more
safely through reduced-intensity allo-HCT. However, it
should be noted that marked improvements have been over
the past decade in supportive care and typing. As such, the
role of conditioning (myeloablative versus RIC) remains an
open question.
Several randomized trials (Table 11) have utilized bio-
logical assignment of patients to prospectively compare
tandem auto-HCT-allo-HCT versus tandem auto-HCT in the
upfront transplantation setting [115-123]. Unrelated donors
were permitted in 1 study [121], whereas all the remaining
studies assigned patients to auto-HCT-allo-HCT if a matched
sibling donor was available. These trials vary substantially in
design, eligibility, pretransplantation induction therapy, use
Table 11
Summary of Randomized Trials Comparing Tandem Auto-HCT-Allo-HCT versus Tandem Auto-HCT
Authors Cooperative
Group
Population, Including
Cytogenetic
Abnormalities
Follow-Up,
mo
Conditioning GVHD
Prophylaxis
Outcomes
Auto, n Auto/
RIC, n
AHCT,
median age
AHCT/allo-HCT,
median age
Auto RIC
Bjorkstrand, 2011 [115];
Gahrton, 2013 [116]
EBMT-NMAM Newly diagnosed
MM patients, <70 yr
96 249 108 57 54 Mel 200 FluþTBI 200 cGy CSA þ MMF Better 8-yr PFS
(22% versus 12%)
and OS (49% versus 39%)
for auto-HCT/allo-HCT
Garban, 2006 [117],
Moreau, 2008 [118]
IFM del13 del þ/ or B2
microglobulin >
3 mg/L and <65 yr
56 219 65 58 54 Mel 200, Mel 220 Bu þ Flu þ ATG CSA þ MTX No difference in PFS or OS
Giaccone [119],
Bruno [120]
NA Newly diagnosed
MM patients, 65 yr
86 82 80 54 (mean) 54 (mean) Mel 200,
Mel 100-200
TBI 200 cGy CSA þ MMF Median PFS (35 versus
29 mo) and OS (80 versus
54 mo) superior in AHCT/
allo-HCT
Knop [121] DSMMM del13 del by FISH,
 60 yr
41 73 126 56 52 Mel 200 Flu þ Mel  ATG NA No difference is OS, PFS
not reported.
Krishnan, 2011 [122] BMT-CTN Not meeting
criteria for
high risk, 70 yr
40 436 189 55 53 Mel 200 TBI 200 cGy CSA þ MMF No difference in 3-yr PFS
or OS
Krishnan, 2011 [122] BMT-CTN del13 del by
cytogenetics or
B2microglobulin>
4 mg/L, 70
40 48 37 57 51 Mel 200 TBI 200 cGy CSA þ MMF No difference in 3-years
PFS or OS
Rosinol, 2008 [123] PETHEMA Not achieving
CR/nCR after ﬁrst
autologous, <65 yr
62 85 25 55 52 Mel 200 or CVB Flu þ Mel CSA þ MTX More CR in AHCT/allo-HCT,
no difference in PFS or OS
EBMT-NMAM indicates European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic Stem Cell Transplantation in Multiple Myeloma (NMAM)2000 study; Flu, ﬂudarabine; CSA, cyclosporine A; MMF,
mycophenolate mofetil; ATG, antithymocyte globulin; NA, not available; PETHEMA, Programa para el Estudio de la Terapéutica en Hemopatía Maligna; CVB, cyclophosphamide, etoposide, BCNU.
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anti-hymoglobulin, and graft-versus-host disease (GVHD)
prophylaxis.
The 2 trials with the longest duration of follow up
[115,116,119,120] (96 and 86 months) are also the only trials
reporting superior PFS and OS among patients assigned to
auto-HCT-allo-HCT. All the remaining studies, including the
largest of the trials performed [122], found no PFS or OS dif-
ference between the 2 approaches. Meta-analyses of the
published allo-HCT versus auto-HCT studies have conﬁrmed
that although CR rates are higher for allo-HCT, so are the rates
of treatment-related mortality [124,125]. Thus, a consistent
PFS or OS beneﬁt for allo-HCT cannot be demonstrated.
Although allo-HCT has been considered for high-risk
groups, the optimal patient population for this strategy is
not known and requires further investigation. Data on late
allo-HCT is scarce, with no prospective randomized trial. A
recent CIBMTR analysis [126] and several single-center
studies [127,128] have suggested that for the multiply
relapsed patient in the salvage setting, allo-HCT does not
offer signiﬁcant advantages in survival or a prospect of cure.
There are also no prospective studies reporting on the
outcome of allo-HCT for plasma cell leukemia (PCL). A
retrospective CIBMTR study of 50 PCL patients who received
allo-HCT or auto-HCT in the ﬁrst 18 months from diagnosis
did not show any advantage of allo-HCT [129], despite lower
relapse rate. Although inconclusive, these data suggest that
in PCL, as inMM, the beneﬁts of lower relapse rates after allo-
HCT are often offset by the high treatment-related mortality.
More tolerable conditioning regimens and advances in sup-
portive care may ultimately allow allo-HCT to have a greater
impact on this high-risk disease.
Lenalidomide maintenance is more controversial in the
allo-HCT setting (versus auto-HCT). It was not feasible and
associated with higher GVHD rates in 1 study [130] whereas
a more recent prospective phase 2 study suggested beneﬁt in
a high-risk MM populationwith a 18 month PFS of 68% [131].
Proteasome inhibitors have been shown to be safe after allo-
HCT and are known to reduce the risk of GVHD in clinical and
experimental settings [132,133]. Newer trials of allo-HCT
incorporating maintenance of either immune modulators
or proteasome inhibitors are being conducted and designed
(ISRCTN16228367 Lena RIC study and BMT CTN1302).
Recommendations on the Role of Allo-HCT
Upfront myeloablative allo-HCT is not routinely recom-
mended (grade A). It may be appropriate for further study in
young patients with very high-risk MM, in the context of a
clinical trial.
Planned RIC-allo-HCT after auto-HCT has not been found
to be superior in the majority of clinical trials and is, there-
fore, not recommended over auto-HCT (grade A). Its role in
high-risk subgroups requires further study.
Allo-HCT salvage therapy for relapsed MM has not been
shown to be superior to salvage auto-HCTand is not routinely
recommended outside of a clinical trial (gradeD). For younger
patients with a good performance status, allo-HCT can be
considered, ideally in the context of a clinical trial.
The role and choice maintenance after allo-HCT has not
been adequately studied and is not known.
CONCLUSIONS
The recent advances in therapy for MM have ushered in
an era in which clinical data cannot always dictate clinical
experience. AlthoughHDCwith auto-HCT is still considered avaluable tool for tumor reduction and remission consolida-
tion, the true data to support this modality in the current
framework of novel therapies are being developed. In these
guidelines, we have attempted to present an objective re-
view of the existing data so that practitioners can make an
educated recommendation to their patients.
The limitations of these recommendations should not be
overlooked. Much of the randomized, controlled, prospective
data comes from trials done before novel triple therapy in-
duction regimens. Much of the data from trials with novel
regimens is single-arm or retrospective. In addition, ad-
vances in supportive care and disease detection increasingly
inﬂuence our decision-making process to tailor treatment for
each individual patient. As patients with MM live longer, the
importance of quality of life cannot be overemphasized.
Future clinical trials with quality of life endpoints will likely
have a signiﬁcant impact on the decision to proceed with
transplantation options.
We await the results of several pivotal trials (BMT CTN
0702, 1304) to further clarify the role and timing of auto-HCT
for MM in the setting of novel therapeutics. In addition, the
equivocal data with allo-HCT combined with poor outcomes
for high-risk patients, regardless of treatment choice, justify
investigating allo-HCT as an up-front therapy for these pa-
tients. This is also being developed as a multicenter clinical
trial (BMT CTN 1302).
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